Latest News

Filters

Filter by tags: Neoplasm Clear all tag filters

13 news articles found

Country operates three commercial Candu reactor units

Source: Nucnet
Date: Wednesday, 27 November 2024
Original article: nucnet.org/news/framatome-and-nucleoelectrica-to-explore-lutetium-177-production-at-argentine-nuclear-plants-11-2-2024

Canadian Nuclear Laboratories (CNL) has received shipments of disused radium-226 sources from the Thailand Institute of Nuclear Technology, which will be recycled to produce actinium-225 to be used in targeted radiotherapy.

Source: World Nuclear News
Date: Thursday, 25 July 2024
Original article: world-nuclear-news.org/Articles/Canada-to-turn-radioactive-sources-from-Thailand-i

October's harvest of cobalt-60, used worldwide to sterilise medical equipment, was the largest since the company began producing the isotope in the 1980s and included two shipments of medical-grade material for therapeutic use.

Source: World Nuclear News
Date: Saturday, 25 November 2023
Original article: world-nuclear-news.org/Articles/Bruce-completes-largest-to-date-radioisotope-deliv

Germany-based radiopharmaceutical biotech company ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories (CNL) have launched Actineer, a joint venture for the industrial-scale production of actinium-225 (Ac-225).

Source: World Nuclear News
Date: Friday, 20 October 2023
Original article: world-nuclear-news.org/Articles/CNL,-ITM-join-up-to-produce-rare-medical-radioisot

TerraPower Isotopes and Belgian joint venture PanTera have announced a collaboration to increase the global availability of actinium-225 (Ac-225), while Arizona-based Serva Energy has developed a new research reactor-based production method to ramp up the supply of the rare radioisotope.

Source: World Nuclear News
Date: Wednesday, 28 June 2023
Original article: world-nuclear-news.org/Articles/Nuclear-innovation-companies-in-new-Ac-225-initiat

Advances in emerging field of ‘theranostics’ are a game-changer Millions of patients around the globe rely on the regular and timely production of diagnostic and therapeutic isotopes produced in research reactors and accelerator facilities. Image courtesy IAEA. Advances in medical isotope diagnostics and therapy are holding promise for cancer patients, despite challenges facing the nuclear medical field in recent years related to radionuclide production and supply, rising costs, and stricter regulation.

Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.

Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.

According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.

Source: Nucnet
Date: Friday, 14 April 2023
Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023

The production of cobalt-60 is critical to healthcare and, with demand soaring, the challenge is to expand supply, writes Martin Comben from the International Irradiation Association.

Source: World Nuclear News
Date: Wednesday, 29 March 2023
Original article: world-nuclear-news.org/Articles/The-critical-production-of-cobalt-60-in-nuclear-re

The commercial production of lutetium-177 (Lu-177) has begun using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a planned maintenance outage earlier this year.

Source: World Nuclear News
Date: Thursday, 27 October 2022
Original article: world-nuclear-news.org/Articles/Bruce-7-starts-producing-innovative-therapeutic-is

Lutetium-177 (Lu-177) has been produced using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a recent planned maintenance outage. It marks the first time the short-lived medical isotope has been produced in a commercial nuclear power reactor.

Source: World Nuclear News
Date: Thursday, 23 June 2022
Original article: world-nuclear-news.org/Articles/Canadian-Candu-produces-cancer-therapy-isotope

The nuclear medicine sector is a small part of the wider nuclear industry, but it provides some of the most pioneering technologies in healthcare - and is close to making personalised medicine a reality. Antonis Kalemis, president of Nuclear Medicine Europe and business manager for molecular imaging at Siemens Healthineers, describes how nuclear medicine also tackles the most trenchant condition in modern healthcare: cancer.

Source: World Nuclear News
Date: Thursday, 29 July 2021
Original article: world-nuclear-news.org/Articles/Viewpoint-Nuclear-medicine-is-crucial-for-fighting

Load more news